摘要
老年或行为状态差(PS≥2)的非小细胞肺癌患者通常对化疗的耐受性较差.表皮生长因子受体酪氨酸激酶抑制剂--吉非替尼副作用轻,耐受性好,使得这一特殊群体可能从中获益.吉非替尼在PS=2～3的患者中有效率为13%～17%,疾病控制率为17.1%～41.6%.在老年患者中,疾病控制率为50%左右.副作用主要是工/Ⅱ级的皮肤病变和腹泻.本文对文献报道的吉非替尼治疗老年和行为状态差的非小细胞肺癌的临床研究进行了总结.
Elderly and poor performance status(PS≥2)advanced non-small-cell lung cancer(NSCLC)patients often tolerate chemotherapy poorly.These special patient groups may benefit from gefitinib—the epidermal growth factor receptor tyrosine kinase inhibitor,which is safe and well tolerated.The response rate with gefitinib in patients with PS 2-3 was 13%-17%,disease control was 17.1%-41.6%.In elderly patients,disease control was about 50%.The side effects were generally grade 1/2 skin toxicity and diarrhea.We undertook a review of the published literature on this topic.
出处
《癌症进展》
2005年第6期556-559,574,共5页
Oncology Progress
关键词
吉非替尼
老年
行为状态
非小细胞肺癌
gefitinib elderly performance status non-small-cell lung cancer
